No disclosed relationships extracted for MISTyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Nothing on the wire mentions MIST yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How MIST has moved on past release days vs its typical ±3.4% day, and how often it closed up. Computed from daily closes — not a forecast.